CN116249787A - 用g蛋白偶联受体75(gpr75)抑制剂治疗肥胖症 - Google Patents

用g蛋白偶联受体75(gpr75)抑制剂治疗肥胖症 Download PDF

Info

Publication number
CN116249787A
CN116249787A CN202180051355.1A CN202180051355A CN116249787A CN 116249787 A CN116249787 A CN 116249787A CN 202180051355 A CN202180051355 A CN 202180051355A CN 116249787 A CN116249787 A CN 116249787A
Authority
CN
China
Prior art keywords
seq
complement
positions
position corresponding
absence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180051355.1A
Other languages
English (en)
Chinese (zh)
Inventor
L·A·洛塔
M·A·R·费雷拉
A·巴拉斯
P·阿克巴里
O·索西纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN116249787A publication Critical patent/CN116249787A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180051355.1A 2020-06-22 2021-06-21 用g蛋白偶联受体75(gpr75)抑制剂治疗肥胖症 Pending CN116249787A (zh)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202063042327P 2020-06-22 2020-06-22
US63/042,327 2020-06-22
US202063066185P 2020-08-15 2020-08-15
US63/066,185 2020-08-15
US202063075858P 2020-09-09 2020-09-09
US63/075,858 2020-09-09
US202063089625P 2020-10-09 2020-10-09
US63/089,625 2020-10-09
US202063104613P 2020-10-23 2020-10-23
US63/104,613 2020-10-23
US202163142632P 2021-01-28 2021-01-28
US63/142,632 2021-01-28
US202163159017P 2021-03-10 2021-03-10
US63/159,017 2021-03-10
US202163210287P 2021-06-14 2021-06-14
US63/210,287 2021-06-14
US202163211061P 2021-06-16 2021-06-16
US63/211,061 2021-06-16
PCT/US2021/038260 WO2021262601A1 (en) 2020-06-22 2021-06-21 Treatment of obesity with g-protein coupled receptor 75 (gpr75) inhibitors

Publications (1)

Publication Number Publication Date
CN116249787A true CN116249787A (zh) 2023-06-09

Family

ID=76943116

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180051355.1A Pending CN116249787A (zh) 2020-06-22 2021-06-21 用g蛋白偶联受体75(gpr75)抑制剂治疗肥胖症

Country Status (10)

Country Link
US (2) US11359246B2 (https=)
EP (1) EP4168548A1 (https=)
JP (1) JP2023531935A (https=)
KR (1) KR20230041709A (https=)
CN (1) CN116249787A (https=)
AU (1) AU2021296270A1 (https=)
CA (1) CA3186576A1 (https=)
IL (1) IL298930A (https=)
MX (1) MX2022016458A (https=)
WO (1) WO2021262601A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120624452A (zh) * 2025-08-12 2025-09-12 苏州吉玛基因股份有限公司 一种抑制GPR75基因表达的siRNA及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11359246B2 (en) * 2020-06-22 2022-06-14 Regeneron Pharmaceuticals, Inc. Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors
EP4225917A1 (en) * 2020-10-05 2023-08-16 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
US20250367321A1 (en) * 2022-06-24 2025-12-04 The Regents Of The University Of California Compositions and methods involving adgrg6
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040790A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
US20080108145A1 (en) 2006-11-07 2008-05-08 Stephanie Chissoe Genes associated with osteoarthritis
US20080108080A1 (en) * 2006-11-07 2008-05-08 Stephanie Chissoe Genes associated with obesity
EP1961825A1 (en) 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
US10446261B1 (en) 2008-01-06 2019-10-15 Biotailor, Inc. System and method for analyzing splicing codes of spliceosomal introns
US8185323B1 (en) 2008-01-06 2012-05-22 Degen Zhuo Method of identifying exons and introns and diagnostic uses thereof
US20110177964A1 (en) 2009-12-03 2011-07-21 The Trustees Of Princeton University Chemosensory arrays
EP2763540A4 (en) * 2011-09-09 2015-04-22 Univ Yale COMPOSITIONS AND METHODS FOR THE EVALUATION AND TREATMENT OF INFLAMMATORY DISEASES AND DISEASES
US20140377278A1 (en) 2012-01-10 2014-12-25 Yale University Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders
WO2015017656A1 (en) 2013-07-31 2015-02-05 The Regents Of The University Of California Methods of diagnosis and treatment for pulmonary arterial hypertension
WO2017004153A1 (en) 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
US20230000912A1 (en) 2016-01-25 2023-01-05 The Broad Institute, Inc. Genetic, developmental and micro-environmental programs in idh-mutant gliomas, compositions of matter and methods of use thereof
US11690825B2 (en) * 2016-03-09 2023-07-04 Board Of Regents, The University Of Texas System 20-HETE receptor (GPR75) antagonists and methods of use
WO2017176672A1 (en) 2016-04-04 2017-10-12 The Regents Of The University Of California Compositions and methods related to polycytotoxic t cells
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CN118108847A (zh) 2016-08-07 2024-05-31 诺华股份有限公司 mRNA介导的免疫方法
US20200113950A1 (en) 2017-06-30 2020-04-16 The Rockefeller University Human microbiota derived N-acyl amides for the treatment of human disease
WO2019036753A1 (en) 2017-08-22 2019-02-28 Monash University SCREENING TESTS, MODULATORS AND MODULATION OF RECEIVER ACTIVATION FOR ADVANCED GLYCATION TERMINAL PRODUCTS (RAGE)
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020118363A1 (en) 2018-12-10 2020-06-18 Monash University Screening assays, modulators and modulation of intracellular signalling mediated by immunoglobulin superfamily cell adhesion molecules
WO2020247220A1 (en) 2019-06-03 2020-12-10 University Of Florida Research Foundation, Inc. Compositions and methods for predicting susceptibility of cancers to synthetic-lethal therapies
US11359246B2 (en) * 2020-06-22 2022-06-14 Regeneron Pharmaceuticals, Inc. Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120624452A (zh) * 2025-08-12 2025-09-12 苏州吉玛基因股份有限公司 一种抑制GPR75基因表达的siRNA及其应用

Also Published As

Publication number Publication date
US20220411870A1 (en) 2022-12-29
IL298930A (en) 2023-02-01
MX2022016458A (es) 2023-04-05
US20220042101A1 (en) 2022-02-10
WO2021262601A1 (en) 2021-12-30
US11359246B2 (en) 2022-06-14
KR20230041709A (ko) 2023-03-24
CA3186576A1 (en) 2021-12-30
EP4168548A1 (en) 2023-04-26
AU2021296270A1 (en) 2023-02-02
JP2023531935A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
US11359246B2 (en) Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors
US20250250631A1 (en) Kelch Domain Containing 7B (KLHDC7B) Variants And Uses Thereof
CN113727732B (zh) 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
CA3191030A1 (en) Treatment of sepsis with pcsk9 and ldlr modulators
CA3167756A1 (en) Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors
WO2023278741A1 (en) Methods of treating decreased bone mineral density with kringle containing transmembrane protein 1 (kremen1) inhibitors
CA3141632A1 (en) Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
EP4114975B1 (en) Fascin-2 (fscn2) variant and use thereof
US20230108957A1 (en) Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors
US20230192864A1 (en) Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors
US20230034093A1 (en) Treatment Of Cognitive Impairment With Alpha-N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 5 (ST6GALNAC5) Inhibitors
WO2023278787A2 (en) Treatment of decreased bone mineral density with wnt family member 5b (wnt5b) inhibitors
JP2024531507A (ja) Ｃａｍｐ応答性エレメント結合タンパク質３様３（ｃｒｅｂ３ｌ３）阻害剤による肝疾患の治療
JP2024524388A6 (ja) Ｗｎｔファミリーメンバー５Ｂ（ＷＮＴ５Ｂ）阻害剤での低下した骨塩密度の処置
JP2024524374A (ja) 溶質輸送体ファミリー９アイソフォームａ３調節因子２（ｓｌｃ９ａ３ｒ２）阻害剤による高血圧症の治療
CA3141309A1 (en) Synaptojanin 2 (synj2) variants and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination